Walleye Capital’s Co-Diagnostics CODX Stock Holding History

Walleye Capital’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,580	Closed	-$441K	–	3245
2022 Q3	$441K	Buy	+4,580	New	+$641K	0.01%	1565

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Walleye Capital's CODX Position: Q4 2022 in Review

Walleye Capital sold out of Co-Diagnostics (CODX) in Q4 2022, closing a stake of 4,580 shares — an estimated $441K sold.

Walleye Capital first reported a position in CODX in Q3 2022 and held it in 1 quarter. The position peaked at $441K in Q3 2022. 59 funds tracked by Wall St. Rank hold CODX as of Q4 2022.

Walleye Capital reported no remaining Co-Diagnostics position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 4,580 Co-Diagnostics shares in Q4 2022, an estimated $441K.
Walleye Capital first reported a position in Co-Diagnostics in Q3 2022 and held it in 1 quarter.
Walleye Capital's Co-Diagnostics position peaked at $441K in Q3 2022.
59 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.